Activities

Altered cellular signalling and immune dysregulation are hallmarks of most auto-immune, inflammatory and chronic viral diseases. The expression, signalling and activity of chemokines and IFN are often altered in these pathologies but the molecular mechanisms and fine regulation at play are not completely understood. Most viruses have evolved strategies to hijack, bypass or lure these signal transducers and cellular effectors to favour their replication and/or to corrupt or evade immunity.

Our research interests revolve around two axes:

  • Fundamental research aiming at gaining new insights into the complex structural and cellular mechanisms that lead to altered cellular signalling and cell transformation.
  • Translational research aiming at developing novel tools and therapeutic approaches to interfere or modulate these processes and viral replication.

Research projects

  • Studying the structure and function of human chemokine receptors CXCR4, CXCR7 and CXCR3 and viral receptors and deciphering homeostatic and pathogenic molecular interactions, signalling and intracellular trafficking induced by their endogenous and viral ligands.
  • Designing novel chemokine-receptor inhibitors interfering with chemokine receptor signalling as well as with HIV entry and developing viral tools for applied research and for determining viral tropism as well as resistance to entry inhibitors.
  • Studying the molecular mechanisms of HIV assembly and viral protein trafficking, paying particular care to the impact of subtype-related variability.
  • Investigating the molecular mechanisms leading from chronic inflammation to cancer development in chronic viral infections, focusing on the role of the Interferon-induced proteins APOBEC3 and SAMHD1 in cellular DNA damage, viral integration of DNA viruses and cellular homeostasis.

Featured Publications

Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds.

  • Immuno-Pharmacology and Interactomics
November 04, 2019
2019 Nov. ACS Pharmacol Transl Sci. In Press.
By:
  • Wouters E
  • Walraed J
  • Robertson MJ
  • Meyrath M
  • Szpakowska M
  • Chevigné A
  • Skiniotis G
  • Stove C.

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in Glioblastoma.

  • Neuro-Oncology Laboratory
  • Immuno-Pharmacology and Interactomics
September 06, 2019
2019 Sep. Neurooncology Adv. Accepted.
By:
  • Neirinckx V
  • Hau A-C
  • Schuster A
  • Fritah S
  • Tiemann K
  • Klein E
  • Nazarov PV
  • Matagne A
  • Szpakowska M
  • Meyrath M
  • Chevigné A
  • Schmidt MHH
  • Niclou SP.
See all publications

Contacts

Andy Chevigne

Ph.D., ADR

29, rue Henri Koch
L-4354 Esch-sur-Alzette
Luxembourg
Tel. : +352 26970-336